HeartSciences Inc. (HSCS)

Market Cap	8.50M +13.7%
Revenue (ttm)	4,319 -0.7%
Net Income	-9.14M
EPS	-3.48
Shares Out	3.90M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,057
Open	2.030
Previous Close	2.080
Day's Range	1.980 - 2.400
52-Week Range	1.630 - 3.930
Beta	1.79
Analysts	Buy
Price Target	10.00 (+358.72%)
Earnings Date	Sep 10, 2026

About HSCS

HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic EC...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 15, 2022
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: HSCS
• Website: https://heartsciences.com

Financial Performance

In fiscal year 2026, HeartSciences's revenue was $4,319, a decrease of -0.71% compared to the previous year's $4,350. Losses were -$9.14 million, 4.30% more than in 2025.

Analyst Summary

According to 2 analysts, the average rating for HSCS stock is "Buy." The 12-month stock price target is $10.0, which is an increase of 358.72% from the latest price.

Price Target

$10.0

(358.72% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 1, 2026

Data Sources Report a data error